Advertisement

Monoamine oxidase and catecholamine metabolism

  • I. J. Kopin
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)

Summary

The enzyme which has come to be known as monoamine oxidase was discovered in liver over 60 years ago as tyramine oxidase (Hare, 1928). Almost 10 years later, Blaschko et al. (1957a,b) established that epinephrine, norepinephrine and dopamine were also substrates for this enzyme. Zeller (1938) distinguished monoamine oxidase as different from several other amine oxidases, such as diamine oxidase. Although it was generally assumed that catecholamines were metabolized by MAO, this was not established until isotopically labelled epinephrine and an MAO inhibitor became available. Schayer (1951) found that after administration of N-methyl-14C-epinephrine, only about 50% of the radioactivity appeared in the urine, whereas when the 14C label was incorporated into the β-position on the side chain, almost all of the radioactivity could be recovered. One year later, Zeller et al. (1952) discovered that isonicotinic acid hydrazide (iproniazid) inhibited MAO. When animals pretreated with the MAO inhibitor were administered N-methyl-14C-epinephrine, almost all of the radioactivity was recovered (Schayer et al., 1955), indicating that the enzyme was responsible for the metabolism of about half of the administered catecholamine. Schayer et al. (1952, 1953) had found that five urinary metabolite products of β-labelled-14C-norepinephrine could be separated by paper chromatography, but the chemical structures of these compounds were not known.

Armstrong et al. (1957) showed that 3-methoxy-4-hydroxymandelic acid (vanillyl mandelic acid, VMA) was the major metabolite of norepinephrine and Shaw et al. (1957) demonstrated that large amounts of homovanillic acid (HVA) were excreted in urine after administration of 3,4-dihydroxy-phenylalanine (DOPA). These observations led Axelrod to examine the possibility that O-methylation might precede deamination and to his discovery of catechol-O-methyl transferase (Axelrod, 1957, 1959). At that time it became apparent that there were two possible routes for metabolism of norepinephrine to VMA — either deamination followed by O-methylation or O-methylation and subsequent deamination. The relative roles of these two pathways in terminating the physiological actions of catecholamines then became a focus of attention. Biochemical methods were used to access directly the relative importance of the two metabolic pathways. Physiological methods, based on the effects of drugs which alter metabolism of the catecholamine, were used to examine the role of MAO and COMT in terminating the actions of administered or endogenously released catecholamines.

Keywords

Monoamine Oxidase Diamine Oxidase Vanillyl Mandelic Acid Isonicotinic Acid Hydrazide Catecholamine Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anden NE, Grabowska-Anden M (1983) Formation of deaminated metabolites of dopamine in noradrenaline neurons. Naunyn Schmiedebergs Arch Pharmacol 324: 1–6.PubMedCrossRefGoogle Scholar
  2. Anden NE, Grabowska-Anden M, Lindgren S, Oweling M (1985) Very rapid turnover of dopamine in noradrenaline cell body regions. Naunyn Schmiedebergs Arch Pharmacol 329: 258–263.PubMedCrossRefGoogle Scholar
  3. Armstrong MD, McMillan A, Shaw KNF (1957) 3-Methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine. Biochem Biophys Acta (Amst) 25: 422–423.CrossRefGoogle Scholar
  4. Axelrod J (1957) O-Methylation of catecholamines in vitro and in vivo. Science 126: 400–401.PubMedCrossRefGoogle Scholar
  5. Axelrod J (1959) The metabolism of catecholamines in vivo and in vitro. Pharmacol Rev 11(Part 2): 402–408.PubMedGoogle Scholar
  6. Axelrod J, Laroche MJ (1959) Inhibitor of O-methylation of epinephrine and norepinephrine in vitro and in vivo. Science 130: 800–801.PubMedCrossRefGoogle Scholar
  7. Axelrod, J, Whitby LG, Hertting G (1961) Effect of psychoactive drugs on the uptake of H3-norepinephrine by tissues. Science 133: 338–384.CrossRefGoogle Scholar
  8. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Haas V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: a long term study. J Neural Transm 64: 113–127.PubMedCrossRefGoogle Scholar
  9. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) Potentiation of antikinetic effect after L-dopa treatment by an inhibitor of MAO-B, L-deprenyl. J Neural Transm 36: 303–323.PubMedCrossRefGoogle Scholar
  10. Blaschko H (1957a) Metabolism and storage of biogenic amines. Experimentia (Basel) 13: 9–12.CrossRefGoogle Scholar
  11. Blaschko H (1957b) Formation of catecholamines in the animal body. Br Med Bull 13: 162–165.PubMedGoogle Scholar
  12. Brown GL, Gillespie JS (1957) Output of sympathetic transmitter from the spleen of the cat. J Physiol (Lond) 138: 81–102.Google Scholar
  13. Celander O, Mellander S (1955) Elimination of adrenaline and noradrenaline from circulating blood. Nature (Lond) 176: 973.CrossRefGoogle Scholar
  14. Corne SJ, Graham JDP (1957) Effect of inhibition of monoamine oxidase in vivo on administered adrenaline, noradrenaline, tyramine and serotonin. J Physiol (Lond) 135: 339–349.Google Scholar
  15. Crane GE (1957) Iproniazid (Marsilid) phosphate: a therapeutic agent for mental disorders and debilitating illness. Psychiat Res Rep Am Psychiat Ass 8: 142–152.Google Scholar
  16. Crout JR (1961) Effect of inhibiting both catechol-O-methyl transferase and monoamine oxidase on cardiovascular responses to norepinephrine. Proc Soc Exp Biol 108: 482–484.PubMedGoogle Scholar
  17. Eisenhofer G, Goldstein DS, Stull R, Ropchak TG, Keiser HR, Kopin IJ (1987) Dihydroxyphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline. Clin Sci 73: 123–127.PubMedGoogle Scholar
  18. Eiesnhofer G, Ropchak TG, Stull RW, Goldstein DS, Keiser HR, Kopin IJ (1987) Dihydoxyphenylglycol and intraneuronal metabolism of endogenous and exogenous norepinephrine in the rat vas deferens. J Pharmacol Exp Ther 142: 547–553.Google Scholar
  19. Griesemer EC, Barsky J, Dragstedt CA, Wells JA, Zeller EA (1953) Potentiating effect of iproniazid on the pharmacological actions of sympathomimetic amines. Proc Soc Exp Biol 84: 699–701.PubMedGoogle Scholar
  20. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Kerier HR, Kopin IJ (1988) Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest 81: 213–220.PubMedCrossRefGoogle Scholar
  21. Graefe KH, Bonisch H (1988) The transport of amines across the axonal membranes of noradrenergic and dopaminergic neurons. In: Catecholamines, vol 90. Springer, Berlin Heidelberg New York Tokyo, pp 193–245.Google Scholar
  22. Hare MLC (1928) Tyramine oxidase. A new enzyme system in liver. Biochem J 22: 968–979.PubMedGoogle Scholar
  23. Hertting G, Axelrod J (1961) Fate of tritiated noradrenaline at the sympathetic nerve endings. Nature 192: 172–173.PubMedCrossRefGoogle Scholar
  24. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain. Biochem Pharmacol 17: 1285–1297.PubMedCrossRefGoogle Scholar
  25. Kendler KS, Heninger GR, Roth RH (1981) Brain contribution to the haloperidolinduced increase in plasma homovanillic acid. Eur J Pharmacol 71: 321–326.PubMedCrossRefGoogle Scholar
  26. Klein NS (1958) Clinical experience with iproniazid (Marsilid). J Clin Exp Psychopathol 19: 72–78.Google Scholar
  27. Knoll J (1978) The possible mechanisms of action of (-)-deprenyl in Parkinson’s disease. J Neural Transm 43: 177–198.PubMedCrossRefGoogle Scholar
  28. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408.PubMedGoogle Scholar
  29. Kopin IJ (1960) Technique for the study of alternative metabolic pathways: epinphrine metabolism in man. Science 131: 1372–1374.PubMedCrossRefGoogle Scholar
  30. Kopin IJ (1968) False adrenergic transmitters. Ann Rev Pharmacol 8: 377–394.PubMedCrossRefGoogle Scholar
  31. Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37: 333–364.PubMedGoogle Scholar
  32. Kopin IJ, Axelrod J (1960) 3,4-Dihydroxyphenylglycol, a metabolite of epinephrine. Arch Biochem Biophys 89: 148–149.PubMedCrossRefGoogle Scholar
  33. Kopin IJ, Axelrod J (1963) The role of monoamine oxidase in the release and metabolism of norepinephrine. Ann NY Acad Sci 107: 848–855.PubMedCrossRefGoogle Scholar
  34. Kopin IJ, Axelrod J, Gordon EK (1961) The metabolic fate of H3-epinephrine and C14-metanephrine in the rat. J Biol Chem 136: 2109–2113.Google Scholar
  35. Kopin IJ, Fischer JE, Musacchio J, Horst WD (1964) Evidence for a false neurochemical transmitter as a mechanism for the hypotensive effect of monoamine oxidase inhibitors. Proc Natl Acad Sci 52: 716–721.PubMedCrossRefGoogle Scholar
  36. Kopin IJ, Gordon EK (1962) Metabolism of norepinephrine-H3 released by tyramine and reserpine. J Pharmacol 138: 351–357.Google Scholar
  37. Kopin IJ, Gordon EK (1963) Metabolism of administered and drug-released norepinephrine-7-H3 in the rat. J Pharmacol 140: 207–216.Google Scholar
  38. Kopin IJ, Harvey-White J, Bankiewicz K (1988a) A new approach to biochemical evaluation of brain dopamine metabolism. Cell Mol Neurobiol 8: 171–179.PubMedCrossRefGoogle Scholar
  39. Kopin IJ, Hertting G, Gordon EK (1962) Fate of norepinephrine-H3 in the isolated perfused rat heart. J Pharmacol Exp Ther 138: 34–40.PubMedGoogle Scholar
  40. Kopin IJ, Oliver JA, Polinsky, RJ (1988b) Relationship between urinary excretion of homovanillic acid and norepinephrine metabolites in normal subjects and patients with orthostatic hypotension. Life Sci 43: 125–131.PubMedCrossRefGoogle Scholar
  41. Kopin IJ, Weise VK (1968) Effect of reserpine and metaraminol on excretion of homovanillic acid and 3-methoxy-4-hydroxyphenylglycol in the rat. Biochem Pharmacol 17: P1461–1464.CrossRefGoogle Scholar
  42. Kopin IJ, Zukowska-Grojec Z, Bayorh MA, Goldstein DS (1984) Estimation of intra-synaptic noradrenaline concentrations at vascular neuroeffector junctions in vivo. Naunyn Schmiedebergs Arch Pharmacol 325: 298–305.PubMedCrossRefGoogle Scholar
  43. LaBrosse EH, Axelrod J, Kety SS (1958) O-Methylation, the principal route of metabolism of epinephrine in man. Science 128: 593–594.PubMedCrossRefGoogle Scholar
  44. Langeloh A, Bonisch H, Trendelenburg U (1987) The mechanism of 3H-noradrenaline releasing effect of various substrates of uptake 1: multifactorial induction of outward transport. Naunyn Schmiedebergs Arch Pharmacol 336: 603–610.Google Scholar
  45. Maas JW, Contreras SA, Bowden CL, Weintraub SE (1985) Effects of debrisoquin on CSF and plasma HVA concentrations in man. Life Sci 36: 165–176.CrossRefGoogle Scholar
  46. Majewski H, Hedler L, Steppeler A, Starke K (1982) Metabolism of endogenous and exogenous noradrenaline in the rabbit perfused heart. Naunyn Schmiedebergs Arch Pharmacol 319: 125–129.PubMedCrossRefGoogle Scholar
  47. Marley E, Blackwell B (1970) Interactions of monoamine oxidase inhibitors, amines and foodstuffs. Adv Pharmacol Chemother 8: 186–239.Google Scholar
  48. Pettinger WA, Korn A, Spieger H, Solomon HM, Porcelinko R, Abrams WB (1969) Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man. Clin Pharmacol Ther 10: 667–674.PubMedGoogle Scholar
  49. Riddle MA, Leckman JF, Cohen DJ, Anderson M, Ort SI, Caruso KA, Shaywitz BA (1986) Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration. J Neural Transm 67: 31–43.PubMedCrossRefGoogle Scholar
  50. Schayer RW (1951) Metabolism of β-C14 DL-adrenaline. J Biol Chem 189: 301–306.PubMedGoogle Scholar
  51. Schayer RW, Smiley RL, Davis KJ, Kobayashi Y (1955) Role of monoamine oxidase in noradrenaline metabolism. Am J Physiol 182: 285–286.PubMedGoogle Scholar
  52. Schayer RW, Smiley RL, Kaplan EH (1952) Metabolism of adrenaline containing isotopic carbon (II). J Biol Chem 198: 545–551.PubMedGoogle Scholar
  53. Schayer RW, Smiley RL, Kennedy J (1953) Metabolism of epinephrine containing isotopic carbon (III). J Biol Chem 202: 425–430.PubMedGoogle Scholar
  54. Schildkraut JJ, Kety S (1967) Biogenic amines and emotion. Science 156: 21–55.PubMedCrossRefGoogle Scholar
  55. Shaw KNF, McMillan A, Armstrong MD (1957) Metabolism of 3,4-dihydroxypheny-lalanine. J Biol Chem 226: 255–266.PubMedGoogle Scholar
  56. Spector S, Prockop D, Shore PA, Brodie BB (1958) Effect of iproniazid on brain levels of norepinephrine and serotonin. Science 127: 704–705.CrossRefGoogle Scholar
  57. Spector S, Shore PA, Brodie BB (1960) Biochemical and pharmacological effects of monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazine propane (JB 516) and 1-phenyl-3-hydrazinobutane. J Pharmacol Exp Ther 128: 15–21.PubMedGoogle Scholar
  58. Starke K, Hedler L, Steppeler A (1981) Metabolism of endogenous and exogenous noradrenaline in guinea-pig atria. Naunyn Schmiedebergs Arch Pharmacol 317: 193–198.PubMedCrossRefGoogle Scholar
  59. Sternberg DE, Heninger GR, Heninger RH (1983) Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. Life Sci 32: 2447–2452.PubMedCrossRefGoogle Scholar
  60. Swann AC, Maas JW, Hattox SE, Landis H (1980) Catecholamine metabolites in human plasma as indices of brain function: effects of debrisoquin. Life Sci 27: 1857–1862.PubMedCrossRefGoogle Scholar
  61. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 41: 519–522.CrossRefGoogle Scholar
  62. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371.CrossRefGoogle Scholar
  63. Vogt M (1959) Catecholamines in brain. Pharmacol Rev 11: 483.PubMedGoogle Scholar
  64. Wylie DW, Archer S, Arnold A (1960) Augmentation of pharmacological properties of catecholamines by O-methyl transferase inhibitors. J Pharmacol Exp Ther 130: 239–244.PubMedGoogle Scholar
  65. Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine oxidase. In: Catecholamines, vol 90. Springer, Berlin Heidelberg New York Tokyo, pp 117–192.Google Scholar
  66. Zeller EA (1938) Über den enzymatischem Abbau von Histamin und Diaminen. Helv Chim Acta 21: 880–890.CrossRefGoogle Scholar
  67. Zeller EA, Barsky J, Berman ER, Fouts JR (1952) Action of isonicotinic acid hydrazide and related compounds on enzymes of brain and other tissues. J Lab Clin Med 40: 965–966.Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • I. J. Kopin
    • 1
  1. 1.National Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesdaUSA

Personalised recommendations